264 related articles for article (PubMed ID: 36109580)
21. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
22. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer.
Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L
Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671
[TBL] [Abstract][Full Text] [Related]
23. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
24. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
[TBL] [Abstract][Full Text] [Related]
25. HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing.
Liu L; Lv Z; Wang M; Zhang D; Liu D; Zhu F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834680
[TBL] [Abstract][Full Text] [Related]
26. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
[TBL] [Abstract][Full Text] [Related]
27. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
28. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Elkateb AS; Nofal S; Ali SA; Atya HB
Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.
Liu Y; Shao K; Yang W; Shen Q; Lu M; Shao Z; Chu S; Wang Y; Wang X; Chen X; Bai J; Wu X
Cell Death Dis; 2024 Jun; 15(6):395. PubMed ID: 38839744
[TBL] [Abstract][Full Text] [Related]
30. TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
Li H; Lan H; Zhang M; Zhao F; An N; Yi C
Dig Dis Sci; 2023 Jul; 68(7):3070-3082. PubMed ID: 36680650
[TBL] [Abstract][Full Text] [Related]
31. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
32. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP.
Zhang W; Lu Z; Kong G; Gao Y; Wang T; Wang Q; Cai N; Wang H; Liu F; Ye L; Zhang X
Mol Cancer; 2014 May; 13():128. PubMed ID: 24886421
[TBL] [Abstract][Full Text] [Related]
34. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
Li X; Li Y; Lian P; Lv Q; Liu F
Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
[TBL] [Abstract][Full Text] [Related]
35. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma.
Liu MR; Shi C; Song QY; Kang MJ; Jiang X; Liu H; Pei DS
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37695069
[TBL] [Abstract][Full Text] [Related]
37. Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma.
Du X; Qi Z; Xu J; Guo M; Zhang X; Yu Z; Cao X; Xia J
Mol Oncol; 2022 Oct; 16(20):3703-3719. PubMed ID: 36062307
[TBL] [Abstract][Full Text] [Related]
38. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
[TBL] [Abstract][Full Text] [Related]
39. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Li Z; Liao X; Hu Y; Li M; Tang M; Zhang S; Mo S; Li X; Chen S; Qian W; Feng R; Yu R; Xu Y; Yuan S; Xie C; Li J
Free Radic Biol Med; 2023 May; 201():41-54. PubMed ID: 36924851
[TBL] [Abstract][Full Text] [Related]
40. Time Course of Changes in Sorafenib-Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phospho-Regulated Signaling in Ferroptosis Induction.
Werth EG; Rajbhandari P; Stockwell BR; Brown LM
Proteomics; 2020 May; 20(10):e2000006. PubMed ID: 32336023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
